Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy

Area of Science:

• Neurology
• Genetics
• Pediatrics

Background:

• Spinal muscular atrophy type 1 (SMA1) is a severe, progressive motor neuron disease affecting infants.
• SMA1 leads to motor milestone failure, respiratory compromise, and often death by age two.
• Current research focuses on gene replacement therapy for SMA1, targeting the survival motor neuron 1 (SMN1) gene.

Purpose of the Study:

• To evaluate the safety and efficacy of gene replacement therapy for spinal muscular atrophy type 1 (SMA1).
• To assess the functional outcomes, including survival and motor development, following gene therapy in SMA1 patients.

Main Methods:

• Fifteen SMA1 patients received a single intravenous dose of an adeno-associated virus serotype 9 vector carrying SMN complementary DNA.
• Patients were divided into low-dose (3 patients) and high-dose (12 patients) treatment groups.
• Safety was the primary outcome; motor function (CHOP INTEND scale) and survival were secondary and exploratory outcomes compared to historical data.

Main Results:

• All 15 patients survived and were event-free at 20 months, a significant improvement over the 8% survival in historical cohorts.
• The high-dose group showed rapid motor function improvement on the CHOP INTEND scale within months of treatment.
• Remarkable motor milestones were achieved: 11 patients sat unassisted, 9 rolled over, 11 fed orally, and 2 walked independently.

Conclusions:

• A single adeno-associated viral vector infusion of SMN complementary DNA significantly improved survival and motor function in SMA1 patients.
• The gene therapy demonstrated superior outcomes compared to natural history data, highlighting its therapeutic potential.
• Further research is warranted to confirm the long-term safety and efficacy of this gene therapy approach for SMA1.